Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance
Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.
You may also be interested in...
US FDA approval of Rubraca's all-comers maintenance therapy for platinum-sensitive ovarian cancer continues model that Zejula and Lynparza used for a broad maintenance indication, with data broken out for germline BRCA mutation-positive patients in the clinical trials section of labeling.
Progenics' radiopharmaceutical using novel surrogate endpoint for US FDA review; CMS seems unimpressed, which doesn't bode well for new technology add-on payment.
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.